AGENUS INC
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- AGENAgenus Inc.0Calm
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Running, no new patientsPhase 2234 patientsMain results: Sep 2027 - AGENAgenus Inc.0Calm
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
FinishedPhase 281 patientsMain results: Jan 5, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
No insider sales or purchases in the last 6 months.
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 5, 2026
- Shared quarterly resultsNews report (8-K)Nov 5, 2026
- Permission to sell new sharesPermission to sell new shares (S-3)Sep 11, 2026
- Signed a major agreementNews report (8-K)Aug 18, 2026
- An executive or board member joined or leftNews report (8-K)Aug 13, 2026
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.